Hematopoietic Stem Cell Marker Selection for Predictable Engraftment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating hematopoietic stem cells (HSCs) using the CD34 protein marker result in heterogeneous populations, leading to unpredictable engraftment outcomes, high reagent costs, and inefficiencies in predicting self-renewal and proliferative capacity, which can cause engraftment failure and increase manufacturing costs.
Innovation Solution
Isolate HSC populations by selecting CD34+ cells that are negative for CD45RA and positive for CD90, optionally using CD133 or CD117 markers, to achieve predictable engraftment potential and reduce the number of cells required for transplantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CD34 protein marker is used to isolate HSCs, then HSC population can be obtained, but the cell population becomes heterogeneous and engraftment prediction becomes unreliable
Solution Approach 1:
The patent segments the heterogeneous CD34+ cell population into distinct subpopulations based on additional surface markers (CD45RA, CD90, CD133, CD117). This segmentation allows identification of specific HSC subsets with consistent engraftment potential, resolving the contradiction between obtaining HSCs and maintaining population homogeneity for reliable prediction.
Solution Approach 2:
The patent applies local quality by defining specific marker expression patterns within the broader CD34+ population. Rather than treating all CD34+ cells uniformly, it identifies cells with particular combinations of marker expressions (e.g., CD34+CD45RA-CD90+ or CD34+CD133+CD117-) that exhibit consistent engraftment properties, thereby achieving both isolation and predictive reliability.
2Quantity of substance
If CD34-expressing cells are used for transplantation, then HSC population is obtained, but large volumes of reagents are required for manipulation increasing cost
Solution Approach 1:
The patent extracts the truly engrafting HSC subset from the larger CD34+ population by applying additional marker-based selection criteria. This extraction yields a smaller, more potent cell population that requires fewer cells for successful transplantation and reduces the volume of reagents needed for genetic manipulation, thereby lowering manufacturing costs.
Solution Approach 2:
The patent changes the selection parameters from solely CD34+ to multi-marker definitions (CD34+CD45RA-CD90+, CD34+CD133+CD117-). This parameter change identifies a more enriched HSC population with higher engraftment efficiency, reducing the quantity of cells and reagents required for successful transplantation and genetic manipulation.
3Reliability
If bulk CD34+ cells are administered at high doses, then engraftment may occur, but adverse events increase and clinical outcomes worsen
Solution Approach 1:
The patent introduces dynamic marker-based selection that adapts to identify the functional HSC subset regardless of the source material. By using multiple markers that dynamically define HSC identity (CD45RA-, CD90+, CD133+, CD117-), the method ensures consistent isolation of engrafting cells while avoiding the adverse events associated with bulk CD34+ cell administration.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
Strategies to assess and/or produce cell populations with predictive engraftment potential are described. The cell populations can be used for a variety of therapeutic and research purposes.